PharmaEssentia Corporation (TPE:6446)
1,380.00
+15.00 (1.10%)
Nov 13, 2026, 1:30 PM CST
PharmaEssentia Revenue
PharmaEssentia had revenue of 7.76B TWD in the quarter ending September 30, 2026, with 99.29% growth. This brings the company's total for the last twelve months to 24.62B, up 78.20% year-over-year. In the year 2025, PharmaEssentia had annual revenue of 15.63B with 60.61% growth. That makes PharmaEssentia the 9,084th largest company in the world by revenue and 245th in Taiwan.
Revenue (ttm)
24.62B
Revenue Growth
+78.20%
P/S Ratio
23.23
Revenue / Employee
187.92M
Employees
131
Market Cap
571.92B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full PharmaEssentia breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.63B | 5.90B | 60.61% |
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 28.49B |
| Bora Pharmaceuticals | 19.56B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.23B |
| TTY Biopharm Company | 6.81B |
| Synmosa Biopharma | 6.68B |
| ScinoPharm Taiwan | 3.04B |
| Center Laboratories | 1.78B |
PharmaEssentia News
- 2 days ago - PharmaEssentia Slides: Investor presentation - Filings
- 4 days ago - PharmaEssentia Slides: Q3 2026 - Filings
- 3 months ago - PharmaEssentia Slides: Q2 2026 - Filings
- 3 months ago - PharmaEssentia Quarterly report: Q2 2026 - Filings
- 6 months ago - PharmaEssentia Quarterly report: Q1 2026 - Filings
- 7 months ago - PharmaEssentia Quarterly report: Q4 2025 - Filings
- 10 months ago - PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft - Nasdaq
- 11 months ago - PharmaEssentia Quarterly report: Q3 2025 - Filings